Biopharmaceutical News and Research

RSS

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.

27 Jun 2015

Bristol-Myers Squibb to establish R&D center in Cambridge Kendall Square innovation cluster

Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Bristol-Myers Squibb, a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster.

27 Jun 2015

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx' therapeutic peptides for cystic fibrosis (CF).

26 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

Eli Lilly and Company today announced that the Court of Appeal has ruled that the Alimta® (pemetrexed disodium) vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the UK patent's expiration in June 2021.

25 Jun 2015

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

24 Jun 2015

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.

23 Jun 2015

PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched next generation risk-based monitoring capabilities, expanding its Perceptive MyTrials Data-Driven Monitoring (DDM) solution.

From Parexel 18 Jun 2015

Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion

In two ancillary studies of two multi-center international clinical trials led by the University of Southern California Eye Institute, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion (VMA), a condition related to the aging eye that could cause permanent vision loss if left untreated.

18 Jun 2015

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.

17 Jun 2015

Wilson Therapeutics supports BIG WOW event to increase awareness of Wilson's Disease

Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced its sponsorship of the first annual Big Walk on Wilson's (BIG WOW). The event will take place on September 19, 2015 in sixteen cities across North America to increase awareness of Wilson's Disease and raise funds for the Wilson Disease Association.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

16 Jun 2015

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).

16 Jun 2015

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority for commercial aseptic filling and testing.

16 Jun 2015

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies.

16 Jun 2015

Biopharmaceutical News and Research

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Bristol-Myers Squibb to establish R&D center in Cambridge Kendall Square innovation cluster

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

UK Court passes verdict in favor of Lilly relating to Alimta vitamin regimen patent claim

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

PAREXEL expands Perceptive MyTrials Data-Driven Monitoring solution

Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion

FDA accepts BiondVax's IND for Multimeric-001 vaccine

Wilson Therapeutics supports BIG WOW event to increase awareness of Wilson's Disease

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Atopix raises additional development capital to investigate OC459 for treatment of asthma

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News